ATE516019T1 - Quellbare dosierform mit gellan-gummit - Google Patents

Quellbare dosierform mit gellan-gummit

Info

Publication number
ATE516019T1
ATE516019T1 AT05739537T AT05739537T ATE516019T1 AT E516019 T1 ATE516019 T1 AT E516019T1 AT 05739537 T AT05739537 T AT 05739537T AT 05739537 T AT05739537 T AT 05739537T AT E516019 T1 ATE516019 T1 AT E516019T1
Authority
AT
Austria
Prior art keywords
dosage form
spindle
glucose
viscosity
oral administration
Prior art date
Application number
AT05739537T
Other languages
English (en)
Inventor
Daniel Bar-Shalom
Lillian Slot
Gina Fischer
Pernille Hemmingsen
Original Assignee
Egalet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egalet Ltd filed Critical Egalet Ltd
Application granted granted Critical
Publication of ATE516019T1 publication Critical patent/ATE516019T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0023—Spoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0046—Cups, bottles or bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Jellies, Jams, And Syrups (AREA)
AT05739537T 2004-05-11 2005-05-11 Quellbare dosierform mit gellan-gummit ATE516019T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400755 2004-05-11
PCT/DK2005/000317 WO2005107713A2 (en) 2004-05-11 2005-05-11 Swellable dosage form comprising gellan gum

Publications (1)

Publication Number Publication Date
ATE516019T1 true ATE516019T1 (de) 2011-07-15

Family

ID=34967246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05739537T ATE516019T1 (de) 2004-05-11 2005-05-11 Quellbare dosierform mit gellan-gummit

Country Status (8)

Country Link
US (2) US8383154B2 (de)
EP (2) EP2258349B1 (de)
JP (1) JP5154924B2 (de)
AT (1) ATE516019T1 (de)
CA (1) CA2566793C (de)
DK (2) DK2258349T3 (de)
ES (2) ES2517244T3 (de)
WO (1) WO2005107713A2 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (de) 2001-09-21 2015-12-23 Egalet Ltd. Polymer-freigabe-system
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
AU2006292672B2 (en) 2005-09-15 2012-04-19 Genzyme Corporation Sachet formulation for amine polymers
JP5507840B2 (ja) * 2005-09-19 2014-05-28 ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグ 口腔粘膜医薬投与形態
WO2008086804A2 (en) * 2007-01-16 2008-07-24 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2155167A2 (de) 2007-06-04 2010-02-24 Egalet A/S Pharmazeutische zusammensetzungen mit gesteuerter freisetzung für verlängerte wirkung
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
JP5569398B2 (ja) 2008-02-29 2014-08-13 フェッローサン メディカル ディバイス エー／エス 止血および／または創傷治癒を促進するための装置
US9237972B2 (en) * 2008-12-16 2016-01-19 Kimberly-Clark Worldwide, Inc. Liquid surfactant compositions that adhere to surfaces and solidify and swell in the presence of water and articles using the same
EP2208493A1 (de) 2009-01-15 2010-07-21 Sandoz AG Verfahren und Vorrichtung zur oralen Anwendung einer Zusammensetzung
NZ594071A (en) * 2009-01-26 2013-01-25 Egalet Ltd Controlled release formulations comprising morphine sulphate for continuous treatment of pain
AU2010211376B2 (en) 2009-02-06 2013-08-22 Egalet Ltd. Pharmaceutical compositions resistant to abuse
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
JP6163289B2 (ja) 2009-03-11 2017-07-12 オメロス コーポレーション 嗜癖の予防および治療のための組成物および方法
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
FR2955252B1 (fr) * 2010-01-21 2012-03-23 Patrick Lesage Materiau d'insertion destine a elargir le sillon gingival
CA2790248A1 (en) 2010-03-15 2011-09-22 Ferrosan Medical Devices A/S A method for promotion of hemostasis and/or wound healing
JP5890951B2 (ja) 2010-09-13 2016-03-22 ベヴ−アールエックス、インク． 不快味マスキング剤を有する水性薬物送達システム
US9132291B2 (en) 2010-10-05 2015-09-15 Dfb Technology, Ltd. Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
PL2672981T3 (pl) 2011-02-11 2018-09-28 Zx Pharma, Llc Wielocząstkowe preparaty l-mentolu i powiązane sposoby
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
JP5226097B2 (ja) * 2011-03-30 2013-07-03 株式会社ファンケル サプリメントを内包する蓋体とサプリメント分散媒を充填したボトルからなるボトル入り飲料
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US8898912B2 (en) * 2011-08-29 2014-12-02 Adam Leffler Spoon delivery device
CN103957894A (zh) * 2011-10-19 2014-07-30 R.P.谢勒技术有限公司 两相药物递送系统
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CN104159527B (zh) 2012-03-06 2017-04-12 弗罗桑医疗设备公司 包含止血糊剂的压力容器
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
US20150140089A1 (en) * 2012-05-08 2015-05-21 Metronomx Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
WO2013185776A1 (en) 2012-06-12 2013-12-19 Ferrosan Medical Devices A/S Dry haemostatic composition
NZ704011A (en) 2012-07-06 2016-04-29 Egalet Ltd Abuse deterrent pharmaceutical compositions for controlled release
WO2014097302A1 (en) * 2012-12-23 2014-06-26 Zelikman Vadim A gellan gum carrier for a medicament, means and method
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
PT2988824T (pt) 2013-04-23 2019-01-30 Zx Pharma Llc Composição multiparticulada revestida entericamente com subrevestimento proteico
EP3010419B1 (de) 2013-06-21 2020-05-20 Ferrosan Medical Devices A/S Vakuumerweiterte trockenzusammensetzung und spritze zum zurückhalten davon
HK1222543A1 (zh) * 2013-06-26 2017-07-07 爱荷华大学研究基金会 经口药物递送装置和其使用方法
EP3079731B1 (de) 2013-12-11 2018-08-08 Ferrosan Medical Devices A/S Trockenzusammensetzung mit extrusionsverstärker
ES2750956T3 (es) 2014-02-13 2020-03-30 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
AU2015253188B2 (en) * 2014-04-29 2017-09-28 The Procter & Gamble Company Bismuth-containing liquid pharmaceutical suspensions
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
CN105560281A (zh) * 2014-10-08 2016-05-11 华仁药业股份有限公司 一种混合糖电解质注射液及其制备方法
AU2015333206B2 (en) 2014-10-13 2019-07-11 Ferrosan Medical Devices A/S. Dry composition for use in haemostasis and wound healing
AU2015371184B2 (en) 2014-12-24 2020-06-25 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US10792301B2 (en) * 2015-02-13 2020-10-06 The University Of Toledo Therapeutic polysaccharide midi-GAGR and related materials and methods
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
BR112017027695A2 (pt) 2015-07-03 2018-09-04 Ferrosan Medical Devices As seringa para retenção e mistura de primeira e segunda substâncias
SI3334709T1 (sl) 2015-08-12 2025-03-31 Incyte Holdings Corporation Soli zaviralca lsd1
CN109310638A (zh) * 2016-05-06 2019-02-05 医师印章有限责任公司 缬草组合物和相关方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10806789B2 (en) * 2017-05-12 2020-10-20 The LIV Group Inc. Composition for enhanced absorption of supplements
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
EP3699223A1 (de) * 2019-02-19 2020-08-26 LANXESS Deutschland GmbH Inline ultraschallkontrolle zur detektion des anvernetzens einer kautschukmischung bei der in situ silanisierung von hellen füllstoffen
CA3159407A1 (en) * 2019-10-28 2021-05-06 R.P. Scherer Technologies, Llc Delayed release softgel capsules in higher ph environment
WO2022011341A1 (en) * 2020-07-10 2022-01-13 Adare Pharmaceuticals, Inc. Swellable oral pharmaceutical compositions
EP4301373A4 (de) * 2021-03-03 2025-01-22 Veramorph LLC Dissoziation von polymermatrixzusammensetzungen von fulvestrant und verfahren zu ihrer herstellung und verwendung
JP2024533431A (ja) * 2021-09-09 2024-09-12 ジュニオン ラブズ ピーティーイー． リミテッド リパーゼ阻害剤を含む高吸収性ハイドロゲル
WO2024064359A2 (en) * 2022-09-25 2024-03-28 Albert Ludwig University Of Freiburg Marine polysaccharide networks
EP4608405A4 (de) 2022-10-25 2025-12-31 Veradermics Incorporated Zusammensetzungen und verfahren zur verwendung für die modifizierte freisetzung von minoxidil
CN115566270A (zh) * 2022-11-02 2023-01-03 江西安驰新能源科技有限公司 一种锂离子电池用电解质及其制备方法
CN116449023B (zh) * 2023-04-10 2024-07-12 浙江伊利康生物技术有限公司 一种血清淀粉样蛋白a检测试剂盒及其制备方法
GB2630304A (en) * 2023-05-22 2024-11-27 Gelteq Ltd Pharmaceutical formulations
TW202513040A (zh) 2023-09-01 2025-04-01 瑞士商赫孚孟拉羅股份公司 製備半固體組成物之新穎方法及其用途
WO2025191578A1 (en) * 2024-03-14 2025-09-18 Softgel Healthcare Private Limited Gummesule dosage form for the improvement of bioavailability and enhanced patient compliance
DE102024111019A1 (de) 2024-04-19 2025-10-23 Gelita Ag Gelmasse zur Herstellung von Weichkapseln oder Filmen, deren Verwendung und Herstellungsverfahren
CN119756467B (zh) * 2024-12-17 2025-10-03 重庆理工大学 一种温湿度原位检测传感器、湿度传感器制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994260A (en) 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US4590075A (en) * 1984-08-27 1986-05-20 Warner-Lambert Company Elastomer encapsulation of flavors and sweeteners, long lasting flavored chewing gum compositions based thereon and process of preparation
US4824681A (en) 1986-12-19 1989-04-25 Warner-Lambert Company Encapsulated sweetener composition for use with chewing gum and edible products
GB8702411D0 (en) * 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
US5234957A (en) 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
WO1992011084A1 (en) 1990-12-17 1992-07-09 Redding Bruce K Jr Microencapsulated sweeteners for use in baked goods
US5126151A (en) 1991-01-24 1992-06-30 Warner-Lambert Company Encapsulation matrix
US5881926A (en) 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
IL108366A (en) * 1993-03-11 1999-11-30 Taro Vit Ind Ltd Semi-solid pharmaceutical compounds and a device for their use
JP2000508649A (ja) 1996-04-16 2000-07-11 ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム 速崩解性経口剤形物
WO1998006385A1 (de) * 1996-08-15 1998-02-19 Losan Pharma Gmbh Gut schluckbare orale arzneiform
EP0946197A1 (de) * 1996-11-29 1999-10-06 Monsanto Company Gleitfähiges formbeständiges (intaktes) gel zur oralen verabreichung biologosch aktiver stoffe
US6326028B1 (en) * 1997-10-31 2001-12-04 Monsanto Company Alginate and gellan gum as tablet coating
JP3524359B2 (ja) 1997-12-26 2004-05-10 伊那食品工業株式会社 咀嚼・嚥下困難者用の摂食補助用糊料
US6071523A (en) 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6474418B2 (en) 2000-12-07 2002-11-05 Frank's International, Inc. Wellbore fluid recovery system and method
IL156533A0 (en) * 2000-12-21 2004-01-04 Oscar M Bassinson Personal medication dispensing card
US6589955B2 (en) 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
CA2461684A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
HRP20020923A2 (en) * 2001-11-23 2003-10-31 Glaxo Group Ltd Pharmaceutical composition
JP3835544B2 (ja) * 2002-09-10 2006-10-18 明治乳業株式会社 ゼリー乾燥物
KR101179541B1 (ko) 2003-04-25 2012-09-05 레킷트 벵키저 헬스케어(유케이)리미티드 증점성 조성물
EP1646367A4 (de) 2003-07-21 2011-06-15 Nesher Solutions Ltd Orale dosierformen mit kontrollierter freisetzung auf gellan gummi-basis eine neue plattformtechnologie für magenretention
US9109434B2 (en) 2013-06-09 2015-08-18 Schlumberger Technology Corporation System and method for estimating oil formation volume factor downhole

Also Published As

Publication number Publication date
EP1758557B1 (de) 2011-07-13
US8383154B2 (en) 2013-02-26
US20120039969A1 (en) 2012-02-16
US8383155B2 (en) 2013-02-26
WO2005107713A3 (en) 2006-05-18
ES2370729T3 (es) 2011-12-22
EP2258349A3 (de) 2012-04-04
JP5154924B2 (ja) 2013-02-27
DK1758557T3 (da) 2011-10-24
JP2007537169A (ja) 2007-12-20
ES2517244T3 (es) 2014-11-03
WO2005107713A2 (en) 2005-11-17
EP1758557A2 (de) 2007-03-07
CA2566793A1 (en) 2005-11-17
EP2258349A2 (de) 2010-12-08
EP2258349B1 (de) 2014-07-16
US20080299199A1 (en) 2008-12-04
CA2566793C (en) 2013-07-16
DK2258349T3 (da) 2014-10-13

Similar Documents

Publication Publication Date Title
ATE516019T1 (de) Quellbare dosierform mit gellan-gummit
US12053552B2 (en) Functional wound dressing
Guyot et al. Injectable, strong and bioadhesive catechol-chitosan hydrogels physically crosslinked using sodium bicarbonate
Chopra et al. Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design
Hsieh et al. Preparation of γ-PGA/chitosan composite tissue engineering matrices
Vashist et al. Interpenetrating biopolymer network based hydrogels for an effective drug delivery system
EP3643328A1 (de) Ph-getriggerter diagnostischer wundverband
Gomaa et al. Laser-engineered dissolving microneedles for active transdermal delivery of nadroparin calcium
CN102559139B (zh) 密封轮胎穿孔的密封剂组合物及其制备方法
Takahashi et al. The importance of size-exclusion characteristics of type I collagen in bonding to dentin matrices
ES2355613T3 (es) Composiciones en dos fases de polímero hidrofóbico superabsorbente.
Silva et al. Dissolvable carboxymethylcellulose microneedles for noninvasive and rapid administration of diclofenac sodium
KR870007693A (ko) 경조직의 프라이밍(priming) 방법
CN106029047A (zh) 化妆用凝胶薄膜及其制备方法
AU2021431616B2 (en) Medical tissue adhesive and preparation method therefor
BR112018069184B1 (pt) Composição de um ou vários componentes para a produção de um hidrogel, método para a produção de um hidrogel (met)acrílico, hidrogel (met)acrílico, material para a injeção de (met) acrílico, e método para a vedação e/ou o preenchimento de fissuras, vazios, falhas e cavidades em uma estrutura de edifício
Bartkowiak et al. Study of viscoelastic, sorption and mucoadhesive properties of selected polymer blends for biomedical applications
Wu et al. Polyurethane‐based bioglue for the repair of arterial ruptures
GB2398496A (en) Suspensions of water-swellable polymer particles which are substantially water-free or contain insufficient water to fully swell the particles
Nguyen et al. Dual-functional injectable hydrogels as antimicrobial and angiogenic therapeutics for dental pulp regeneration
CN103707587B (zh) 多层peg-dma水凝胶的制备方法
KR20160101957A (ko) 제어가능하게 분해가능한 조성물 및 방법
BR112018071272B1 (pt) Hidrogel (met)acrílico, método para produzir o referido hidrogel (met)acrílico, método para vedação e/ou preenchimento de fissuras, espaços vazios, falhas e cavidades em uma estrutura de construção
WO2021165558A1 (es) Capsula galénica rompible
CN117122729A (zh) 一种组织粘附性水凝胶的制备方法及其应用

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1758557

Country of ref document: EP